Traws Pharma (NASDAQ:TRAW) is a biotechnology company focused on the research, development, and commercialization of novel therapeutics for rare and underserved diseases. Established in 2003 and headquartered in Boston, Massachusetts, the company has built a portfolio of small-molecule and biologic candidates targeting genetic disorders, neurodegenerative diseases, and specialty oncology indications. Following its initial public offering in 2021, Traws Pharma has expanded its research capabilities and advanced multiple pipeline programs through clinical milestones.
The company’s core activities encompass drug discovery, preclinical development, and clinical trials. Traws Pharma operates state-of-the-art laboratories where integrated teams of medicinal chemists, molecular biologists, and pharmacologists work to optimize therapeutic candidates. In addition to internal programs, Traws Pharma offers contract research services—including formulation development and pharmacokinetic studies—to academic institutions and emerging biotech firms seeking specialized expertise in early-stage drug development.
With a global footprint, Traws Pharma maintains research and manufacturing sites in North America and Europe, and strategic partnerships in Asia to support clinical trials and commercial supply. The company’s manufacturing arm produces both active pharmaceutical ingredients and finished-dose formulations in compliance with current Good Manufacturing Practices (cGMP). Through alliances with regional distributors, Traws Pharma ensures the timely delivery of its licensed products to hospitals and specialty pharmacies across key markets, including the United States, United Kingdom, Germany, and Japan.
Under the leadership of President and CEO Dr. Alexandra Reid, Traws Pharma has prioritized a patient-centric approach that balances scientific rigor with regulatory strategy. The executive team, composed of seasoned professionals from leading pharmaceutical and biotech organizations, emphasizes cross-functional collaboration to accelerate development timelines. Looking ahead, Traws Pharma aims to advance its late-stage candidates toward regulatory approval and to expand its service offerings in biologics manufacturing, reinforcing its position as a versatile partner in the global life sciences ecosystem.
AI Generated. May Contain Errors.
Free TRAW Stock Alerts